<< Back To Search

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT06375044
Age 18 +
Sex Both
Phase Phase 1
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The study involves a unique combination of therapies that have not been widely tested together before.
  • It aims to evaluate the effectiveness of this combination in treating patients who have not responded well to standard treatments.
  • Participants will receive the new treatment regimen and will be closely monitored for their response and any side effects.
  • The study is designed to gather data on how well the treatment works and how it can be improved for future patients.
  • Researchers are particularly interested in understanding the long-term effects of this treatment on patients' health and quality of life.
Overall, this study represents an innovative approach to treatment, potentially offering new hope for patients who have limited options available to them.
Third Opinion AI Generated Synopsis

Trial Summary
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: